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A B S T R A C T
Epoxyeicosatrienoic acids (EETs) are important vasoactive products of arachidonic acid metabolism with a wide
range of biological actions in the cardiovascular system. The present study investigated whether single nucleotide
polymorphisms (SNP) of genes coding cytochrome P450 2C subfamily, enzymes involved in biosynthesis of EETs,
are associated with the risk of coronary heart disease (CHD). A total of 1255 unrelated Russian subjects com-
prising 561 patients with angiographically diagnosed CHD and 694 age- and sex-matched healthy subjects were
included in the study. DNA samples from all study participants were genotyped for six common SNPs rs7909236,
rs1934953 of CYP2C8, rs9332242, rs4918758 and rs61886769 of CYP2C9 and rs4244285 of CYP2C19 using by
the Mass-ARRAY 4 system. SNP rs4918758 of CYP2C9 was associated with decreased risk of CHD (codominant
model) at a borderline significance with odds ratio adjusted for sex and age 0.61 (95% CI: 0.41–0.92, P = 0.038,
Q = 0.20). SNP rs9332242 of CYP2C9 showed a trend towards association with increased CHD risk in ciga-
rette smokers (P = 0.049, Q = 0.29). Log-likelihood ratio test (LRT) pointed out epistatic interactions between
rs9332242 and rs61886769 of CYP2C9 (codominant model, P⁠interaction = 0.02), however, this P-value did not sur-
vive after correction for multiple tests. Bioinformatic analysis revealed a regulatory potential for a majority of
the investigated SNPs. Our preliminary results demonstrate that polymorphisms of genes encoding CYP2C sub-
family represent potential genetic markers of CHD susceptibility. Further studies are required to substantiate the
contribution of these genes to the disease risk.
1. Introduction
Coronary heart disease (CHD) is a common cardiovascular disorder
(CVD), a leading cause of mortality and disability worldwide (Roger et
al., 2012). CHD is the primary cause of death in the Russian Federa-
tion, accounting for 45.3% of total CVD direct health care costs (∼$3.1
billion) in the country (Notzon et al., 1998; Kontsevaya et al., 2013).
Coronary heart disease is thought to be complex multifactorial disor-
der resulting from the interaction between multiple genetic and envi-
ronmental factors (Poulter, 1999; Arnett et al., 2007). Genome-wide as-
sociation studies have identified a number of genes related with CHD
susceptibility in different populations of the world and provided insights
into the molecular basis of the disease (Nikpay et al., 2015; McPherson
and Tybjaerg-Hansen, 2016). However, the effect sizes of the identified
loci responsible for CHD susceptibility were for the most part modest
Abbreviations: AA, arachidonic acid; CHD, coronary heart disease; CI, confidence intervals; CVD, cardiovascular disorder; EETs, epoxyeicosatrienoic acids; FDR, false discovery rate;
HWE, Hardy-Weinberg equilibrium; LRT, log-likelihood ratio test; OR, odds ratio; PCR, polymerase chain reaction; ROS, reactive oxygen species; SNP, single nucleotide polymorphism;
TFBS, transcription factor binding site; UTR, untranslated region.
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and collectively explained only a small fraction of the overall heritabil-
ity (Hartiala et al., 2017), dictating the need of further investigation for
understanding disease pathophysiology.
Alterations in the metabolism of arachidonic acid (AA) and other
polyunsaturated fatty acids are known to be involved into the pathogen-
esis of CHD (Theken et al., 2012; Bellien and Joannides, 2013). Epoxye-
icosatrienoic acids (EETs) are important vasoactive products of AA me-
tabolism with a wide range of biological actions in the cardiovascular
system (Bellien and Joannides, 2013; Spiecker and Liao, 2005; Seubert
et al., 2007; Spector and Kim, 1851). Activating upon endogenous stim-
uli and oxidized by cytochrome P450 family 2 (CYP2) epoxygenases,
EETs realize their cardiovascular effects through activating receptor-me-
diated signaling pathways and ion channels and possess vasodilatory,
angiogenic and anti-inflammatory properties in the heart, vasculature
and kidney (Spiecker and Liao, 2005; Spector and Kim, 1851; Fleming,
2001; Zordoky and El-Kadi, 2010). The CYP2 epoxygenases are found in
the heart, vascular smooth muscle and endothelial cells where they are
directly are involved in the biosynthesis of EETs from AA (Spiecker and
Liao, 2005; Spector and Kim, 1851; Fleming, 2001; Zeldin, 2001).
Pursuing an interest in important cardiovascular functions of EETs,
polymorphisms of genes encoding cytochrome P450 family 2 members
became attractive candidates for genetic association studies of coronary
heart disease (Lee et al., 2007; Ercan et al., 2008; Börgel et al., 2008;
Marciante et al., 2008; Rothenbacher et al., 2013; Tang et al., 2016).
Although some studies have revealed a relationship between genetic
variants of CYP2 enzymes and CHD risk, nevertheless, most of them
have yielded controversial results, showing that the pathogenetic role
of these genes needs be clarified by independent studies. No studies
have been done so far to investigate the contribution of genes encoding
cytochrome P450 CYP2C subfamily to CHD susceptibility in Russians.
Therefore, the purpose of this study was to investigate whether common
single nucleotide polymorphisms (SNPs) of the CYP2C genes are associ-
ated with susceptibility to coronary heart disease in Russian population.
2. Methods
2.1. Study participants
Written informed consent was obtained from each study partici-
pant and the study protocol was approved by Ethical Review Commit-
tee of Kursk State Medical University. A total of 1255 unrelated Russ-
ian subjects comprising 561 patients with coronary heart disease and
694 healthy controls were included in this study. All patients with CHD
were enrolled from Cardiology Divisions of Kursk Regional Clinical Hos-
pital and Kursk Emergency Hospital as well as from Regional Cardio-
vascular Centre during a period between 2012 and 2015. All recruited
patients had clinical signs or a history of CHD (angina or myocardial
infarction) and angiographically confirmed narrowing of the coronary
vessels by at least 50% in one or more major coronary artery. None
of the enrolled CHD patients had signs and/or histories of congeni-
tal heart disease, cardiomyopathy, malignancy, connective-tissue dis-
order, chronic inflammatory disease, liver or kidney disease. The con-
trol group included blood donors, healthy volunteers as well as hos-
pital-based patients recruited from surgical, traumatic, infectious divi-
sions of Kursk hospitals without cardiovascular and other chronic dis-
eases. The control group was recruited over several periods in the frame-
work of our previous studies (Polonikov et al., 2007; Polonikov et al.,
2008; Polonikov et al., 2009; Bushueva et al., 2014; Polonikov et al.,
2015; Polonikov et al., 2017). Demographic and clinical characteris-
tics of the study subjects are listed in Table 1. As can be seen from
Table 1, the group of CHD patients was matched to the control group
on both sex and age (P > 0.05). A percentage of positive family history
Table 1
Demographic and clinical characteristics of the study patients.
Baseline characteristics
Controls,
n = 694
CAD
patients,
n = 561 P-value
Age, mean ± standard
deviation
60.8 ± 9.0 61.7 ± 9.3 0.08
Males, n (%) 355 (51.2) 313 (55.8) 0.10
Body mass index (kg/m ⁠2),
mean ± standard deviation
27.9 ± 7.4 28.4 ± 8.3 0.26
Hypertension, n (%) 0 (0.0) 455 (89.2) –
Diabetes, n (%) 0 (0.0) 43 (8.3) –
Smokers (ever/never), n
(%)
246 (36.7) 202 (38.9) 0.43
Positive family history of
CHD, n (%)
137 (21.9) 159 (31.5) 0.0003
Positive family history of
hypertension, n (%)
63 (12.5) 164 (26.3) < 0.0001
Positive family history of
diabetes, n (%)
23 (3.7) 75 (14.8) < 0.0001
Bolded is statistically significant P-value.
of CHD, hypertension, diabetes mellitus was significantly greater in the
case group versus healthy controls. No differences were found between
the groups regarding to other characteristics shown in Table 1.
2.2. Selection of genes and SNPs
Genes encoding CYP2C subfamily were selected on the basis of their
involvement in the biosynthesis of EETs using information available
at the KEGG PATHWAY (www.genome.jp/kegg/pathway.html), Reac-
tome Pathway (www.reactome.org) and PharmGKB (www.pharmgkb.
org) databases. Six common polymorphisms such as rs7909236,
rs1934953 of CYP2C8, rs9332242, rs4918758 and rs61886769 of
CYP2C9 and rs4244285 of CYP2C19 were selected based on their
known functional relevance and/or haplotype tagging properties. The
functionality of the SNPs was assessed in silico by the SNP Function
Prediction tool developed by Xu and Taylor (Xu and Taylor, 2009)
and available online at the SNPinfo Web Server (https://snpinfo.niehs.
nih.gov/snpinfo/snpfunc.htm). Common SNPs such as rs11572103,
rs11572080 and rs10509681 of CYP2C8 as well as rs1799853 and
rs1057910 of CYP2C9 were not included in the study because they have
not been confirmed to be associated with CHD risk by two indepen-
dent studies (Kaur-Knudsen et al., 2009; Haschke-Becher et al., 2010).
Among polymorphisms of the CYP2C19 gene, the only SNP rs4244285
was selected for our study because it is the most common variant asso-
ciated with the formation of a dysfunctional protein (Desta et al., 2002).
2.3. Genotyping
Genomic DNA was extracted by standard phenol/chloroform proce-
dure from whole blood samples obtained from all study participants.
Polymerase Chain Reaction (PCR) was performed on the CFX96
Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories, USA).
SNP genotyping was performed using by the Mass-ARRAY 4 system
(Agena Bioscience Inc., San Diego, CA, USA) at the Core Facility “Med-
ical Genomics” in the Research Institute of Medical Genetics, Tomsk Na-
tional Medical Research Center (Tomsk, Russia). Blind replicates were
included for quality control.
2.4. Data analysis
An association analysis between SNPs and CHD risk could detect
a difference of 4–7% in the genotype distributions between the cases
and controls assuming 75–98% statistical power and a 5% type I error
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(α = 0.05) on the basis of the sample sizes of 561 CHD patients and 694
healthy controls. Allele frequencies were estimated by the gene count-
ing method, and the chi-squire test was used to assess significant de-
partures from Hardy–Weinberg equilibrium. Categorical variables were
also compared by using the chi-squire test. Allele, genotype and hap-
lotype frequencies in the study groups were evaluated by SNPStats,
software which has been designed to analyze genetic associations us-
ing SNPs (Solé et al., 2006). The association between genotypes and
CHD risk was measured by multiple logistic regression analysis to cal-
culate odds ratios (OR) with 95% confidence intervals (CI) and adjusted
for age and gender at codominant genetic model. Statistical calcula-
tions were performed by using the SNPassoc package for R (González
et al., 2007) and SNPStats software (Solé et al., 2006). Epistatic inter-
actions between SNPs were analyzed by SNPassoc package for R us-
ing a log-likelihood ratio test (LRT) (González et al., 2007) and assum-
ing codominant, dominant and recessive models. Haplotypes of CYP2C8
and CYP2C9 were estimated in entire groups of CHD patients and con-
trols using by the SNPStats software. P-value ≤ 0.05 was set to be sta-
tistically significant. As an adjustment for multiple testing, false discov-
ery rate (FDR) based Q-value was calculated for each SNP using the
method proposed by Benjamini and Hochberg (1995) and implemented
in the FDR calculator available online at http://www.sdmproject.com/
utilities/?show=FDR. Significance of the associations was assessed by a
0.20 threshold of Q-value, as previously suggested (Smith et al., 2007).
The regulatory potential of the studied SNPs was evaluated by us-
ing the SNP Function Prediction tool (https://snpinfo.niehs.nih.gov/
snpinfo/snpfunc.php) (Xu and Taylor, 2009) utilizing an information of
the TRANSFAC database on potential transcription factor recognition
sites (BIOBASE Corporation, Wolfenbuettel, Germany). Only transcrip-
tion factor binding sites (TFBS) whose core or matrix match score was
impacted, or which were eliminated or created by variant sequences
are considered to be regulatory within a particular SNP. The SNP Func-
tion Prediction tool was also utilized to scan the SNPs for the pres-
ence of potential binding sites for microRNAs (miRNAs). In addition,
rSNPBase, a database of curated regulatory SNPs (http://rsnp.psych.ac.
cn) (Guo et al., 2014) and functional in vitro studies available from the
literature were used to analyze and interpret genotype-phenotype rela-
tionships.
3. Results
3.1. Association analysis between CYP2C gene subfamily and CHD risk
Table 2 shows the genotype and allele frequencies of CYP2C poly-
morphisms. Allele and genotype frequencies were compatible with those
reported in other European populations (the 1000 Genomes Project,
http://www.internationalgenome.org). The genotype distribution for
majority of SNPs was consistent with the population being in
Hardy-Weinberg equilibrium, HWE (P > 0.05). A significant departure
of genotype frequencies from HWE was found only for SNP rs4244285
of CYP2C19 (P = 0.02). As can be seen from Table 2, SNP rs4918758
of CYP2C9 was associated with decreased risk of CHD at a border-
line significance with odds ratio adjusted for sex and age 0.61 (95%
CI: 0.41–0.92, P = 0.038, Q = 0.20). Gender-stratified analysis (Sup-
plementary Table 1) revealed no differences in allele and genotype fre-
quencies between the case and control groups in both males and females
(P > 0.05).
3.2. Interactions between SNPs of CYP2C gene subfamily and CHD risk
Then log-likelihood ratio test was performed to look for epista-
tic interaction between SNPs that determine the susceptibility to CHD
(Table 3). As can be seen from Table 3, SNP rs4918758 of CYP2C9
(P = 0.011), rs9332242 of CYP2C9 (P = 0.039), rs4244285 of
CYP2C19 (P = 0.031) showed the main effects on CHD risk (recessive
genetic model), as determined by the LRT. In addition, the log-like-
lihood ratio test analysis identified epistatic interactions between
rs9332242 and rs61886769 of CYP2C9 (codominant model,
P⁠interaction = 0.02). However, these P-values did not survive after correc-
tion for multiple tests.
Table 2
Genotype and allele frequencies for SNPs of the CYP2C gene family in CHD patients and healthy controls.
Gene, polymorphism Genotype, allele
Controls, n = 694
n (%)⁠a
CHD patients, n = 561
n (%)⁠a OR (95 CI) ⁠b P-value Q-value
CYP2C8, G > T (rs7909236) G/G 422 (60.8) 316 (56.3) 1.00 0.19 0.29
G/T 239 (34.4) 210 (37.4) 1.19 (0.94–1.50)
T/T 33 (4.8) 35 (6.2) 1.42 (0.86–2.34)
T 305 (22.0) 280 (25.0) 1.18 (0.98–1.42) 0.08 0.27
CYP2C8, T > C (rs1934953) T/T 316 (45.5) 245 (43.7) 1.00 0.56 0.67
T/C 314 (45.2) 255 (45.5) 1.04 (0.82–1.32)
C/C 64 (9.2) 61 (10.9) 1.24 (0.84–1.83)
C 442 (31.8) 377 (33.6) 1.08 (0.92–1.28) 0.35 0.39
CYP2C9, C > G (rs9332242) C/C 557 (80.4) 458 (81.6) 1.00 0.10 0.20
C/G 124 (17.9) 100 (17.8) 1.00 (0.75–1.34)
G/G 12 (1.7) 3 (0.5) 0.29 (0.08–1.02)
G 148 (10.7) 106 (9.4) 0.87 (0.67–1.14) 0.31 0.39
CYP2C9, T > C (rs4918758) T/T 310 (44.7) 262 (46.7) 1.00 0.038 0.20
T/C 302 (43.5) 257 (45.8) 1.01 (0.80–1.28)
C/C 82 (11.8) 42 (7.5) 0.61 (0.41–0.92)
C 466 (33.6) 341 (30.4) 0.86 (0.73–1.02) 0.09 0.27
CYP2C9, T > C (rs61886769) T/T 451 (65) 377 (67.2) 1.00 0.67 0.67
T/C 220 (31.7) 168 (29.9) 0.91 (0.72–1.17)
C/C 23 (3.3) 16 (2.8) 0.81 (0.42–1.57)
C 266 (19.2) 200 (17.8) 0.91 (0.75–1.12) 0.39 0.39
CYP2C19, G > A (rs4244285) G/G 543 (78.2) 448 (79.9) 1.00 0.086 0.20
G/A 130 (18.7) 106 (18.9) 1.00 (0.75–1.33)
A/A 21 (3) 7 (1.2) 0.40 (0.17–0.95)
A 172 (12.4) 120 (10.7) 0.85 (0.66–1.08) 0.19 0.38
a Absolute number and percentage of individuals/chromosomes with particular genotype/allele.
b Odds ratio with 95% confidence intervals adjusted for age and gender.
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Table 3
Epistatic interactions between CYP2C family gene polymorphisms in CHD (gene-gene interactions are evaluated by SNPassoc package for R (González et al., 2007)).
The upper part of the matrix contains the P-values for epistatic interactions evaluated by log-likelihood ratio (LRT) test. The diagonal contains the main effects P-values from LRT for each
SNP. The lower triangle contains the P-values from LRT comparing the two-SNP additive likelihood to the best of the single-SNP models. Bolded are statistically significant P-values for
SNP-SNP interactions. P-values are adjusted for age and gender. All P-values are not adjusted for multiple tests.
3.3. Analysis of haplotypes and linkage disequilibrium between SNPs
The patterns of estimated haplotypes and their frequencies in the
case and control groups are shown in Table 4. Three haplotypes of
the CYP2C8 gene and four haplotypes of the CYP2C9 gene with a fre
Table 4
Estimated haplotype frequencies in CHD patients and controls.
Haplotypes⁠a Controls
CHD
patients OR (95 CI) ⁠b
P-
value
SNPs G > T (rs7909236) and T > C (rs1934953) of CYP2C8
1 G-T 0.6735 0.6551 1.00 –
2 T-C 0.2116 0.2407 1.17
(0.97–1.42)
0.11
3 G-C 0.1068 0.0954 0.92
(0.70–1.20)
0.52
Global haplotype association P-value: 0.29
SNPs C > G (rs9332242), T > C (rs4918758) and T > C (rs61886769) of CYP2C9
1 C-
T-T
0.6598 0.6941 1.00 –
2 C-
C-T
0.1431 0.1267 0.85
(0.67–1.07)
0.16
3 G-
C-C
0.1003 0.0935 0.89
(0.68–1.17)
0.40
4 C-
C-C
0.0896 0.0837 0.87
(0.65–1.17)
0.36
Global haplotype association P-value: 0.16
a Rare haplotypes with frequency < 0.01 are not shown.
b Odds ratio with 95% confidence intervals adjusted for age and gender.
quency > 1% have been identified in the study patients. Haplotype fre-
quencies of CYP2C8 and CYP2C9 were compared between CHD patients
and controls using a chi-square test (Table 4). There was no signifi-
cant difference in the haplotype distribution of CYP2C8 and CYP2C9
between the case and control groups (P > 0.05). Polymorphisms
rs7909236 and rs1934953 of the CYP2C8 gene were in positive linkage
disequilibrium (D′ = 0.946, P < 0.0001), indicating that the wild type
allele at one site is more likely to be associated with the wild type allele
at the other site. All three polymorphisms of CYP2C9 were in a strong
linkage disequilibrium to each other (D′ = 0.958–0.989, P < 0.0001).
3.4. Analysis of SNP-smoking interactions
Table 5 shows the results of analysis for SNP-smoking interactions
and their contribution to CHD risk at codominant genetic model. As
can be seen from Table 5, SNP rs9332242 of CYP2C9 showed a trend
towards association with increased risk of coronary heart disease in
cigarette smokers (P = 0.049, Q = 0.29). No SNP-smoking interactions
were found for other polymorphisms.
3.5. Bioinformatic analysis for regulatory potential of SNPs
Results of bioinformatic analysis for the regulatory potential of the
studied SNPs are shown in Table 6. The SNP Function Prediction tool
allowed identifying putative transcription factor binding sites at SNPs
rs7909236 of CYP2C8, rs4918758 and rs61886769 of CYP2C9 as well
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Table 5
SNP-smoking interactions and susceptibility to CHD.
Genotype Smokers Non-smokers
Controls, n
(%)
CHD patients, n
(%) OR (95% CI) ⁠a
P-
value
Controls, n
(%)
CHD patients, n
(%) OR (95% CI) ⁠a
P-
value
SNP rs7909236 of CYP2C8
G/G 151 (61.4) 125 (61.9) 1.00 – 256 (60.2) 165 (52.1) 0.83
(0.58–1.18)
NS
G/T 87 (35.4) 66 (32.7) 0.93
(0.62–1.39)
NS 145 (34.1) 131 (41.3) 1.17
(0.80–1.71)
NS
T/T 8 (3.3) 11 (5.4) 1.69
(0.66–4.34)
NS 24 (5.6) 21 (6.6) 1.11
(0.57–2.15)
NS
SNP × smoking interaction P-value: 0.21 (Q-value = 0.39)
SNP rs1934953 of CYP2C8
T/T 107 (43.5) 97 (48.0) 1.00 – 199 (46.8) 129 (40.7) 0.75
(0.51–1.12)
NS
T/C 118 (48.0) 89 (44.1) 0.83
(0.56–1.22)
NS 186 (43.8) 151 (47.6) 0.94
(0.64–1.39)
NS
C/C 21 (8.5) 16 (7.9) 0.85
(0.42–1.73)
NS 40 (9.4) 37 (11.7) 1.07
(0.61–1.85)
NS
SNP × smoking interaction P-value: 0.20 (Q-value = 0.39)
SNP rs9332242 of CYP2C9
C/C 204 (82.9) 155 (76.7) 1.00 – 333 (78.5) 267 (84.2) 1.10
(0.81–1.51)
NS
C/G 38 (15.4) 46 (22.8) 1.61
(1.00–2.60)
0.048 83 (19.6) 49 (15.5) 0.83
(0.53–1.31)
NS
G/G 4 (1.6) 1 (0.5) 0.31
(0.03–2.79)
NS 8 (1.9) 1 (0.3) 0.17
(0.02–1.35)
NS
SNP × smoking interaction P-value: 0.049 (Q-value = 0.29)
SNP rs4918758 of CYP2C9
T/T 111 (45.1) 87 (43.1) 1.00 – 189 (44.5) 154 (48.6) 1.09
(0.74–1.61)
NS
T/C 105 (42.7) 100 (49.5) 1.21
(0.82–1.80)
NS 187 (44.0) 139 (43.8) 1.00
(0.67–1.49)
NS
C/C 30 (12.2) 15 (7.4) 0.62
(0.32–1.23)
NS 49 (11.5) 24 (7.6) 0.67
(0.37–1.21)
NS
SNP × smoking interaction P-value: 0.52 (Q-value = 0.62)
SNP rs61886769 of CYP2C9
T/T 160 (65.0) 126 (62.4) 1.00 – 275 (64.7) 225 (71.0) 1.09
(0.78–1.54)
NS
T/C 78 (31.7) 68 (33.7) 1.10
(0.74–1.64)
NS 135 (31.8) 85 (26.8) 0.85
(0.57–1.26)
NS
C/C 8 (3.3) 8 (4.0) 1.22
(0.45–3.36)
NS 15 (3.5) 7 (2.2) 0.63
(0.24–1.61)
NS
SNP × smoking interaction P-value: 0.26 (Q-value = 0.39)
SNP rs4244285 of CYP2C19
G/G 192 (78.0) 162 (80.2) 1.00 – 336 (79.1) 248 (78.2) 0.92
(0.67–1.27)
NS
G/A 47 (19.1) 38 (18.8) 0.95
(0.59–1.53)
NS 76 (17.9) 64 (20.2) 1.07
(0.70–1.65)
NS
A/A 7 (2.8) 2 (1.0) 0.34
(0.07–1.66)
NS 13 (3.1) 5 (1.6) 0.47
(0.16–1.36)
NS
SNP × smoking interaction P-value: 0.75 (Q-value = 0.75)
NS means non-significant.
a Odds ratio with 95% confidence intervals adjusted for age and gender (codominant genetic model).
as microRNA-binding sites and/or RNA binding protein mediated reg-
ulation sites at SNPs rs1934953 of CYP2C8, rs9332242 of CYP2C9 and
rs4244285 of CYP2C19. The lists of TFBS (rs4918758 and rs61886769
of CYP2C9, rs7909236 of CYP2C8) and microRNA-binding sites
(rs9332242 of CYP2C9) are presented in Supplementary Tables 2–4 and
5, respectively.
4. Discussion
4.1. Summary of the study findings
To our knowledge, this is the first study investigated the contribution
of SNPs rs7909236, rs1934953 of CYP2C8 and rs9332242, rs4918758,
rs61886769 of CYP2C9 to the risk of coronary heart disease. We found
that SNP rs4918758 of the CYP2C9 gene is associated with decreased
risk of CHD. The log-likelihood ratio test showed that SNP rs4918758
of CYP2C9, rs9332242 of CYP2C9, rs4244285 of
CYP2C19 have the main effects on CHD risk, and epistatic interactions
between rs9332242 and rs61886769 of CYP2C9 contribute to disease
susceptibility. Moreover, SNP rs9332242 of CYP2C9 showed a sugges-
tive association with increased risk of coronary heart disease in ciga-
rette smokers (P = 0.049, Q = 0.29). Bioinformatic analysis revealed
the functionality of the studied SNPs: the presence of multiple puta-
tive TFBS at SNPs rs7909236 of CYP2C8, rs4918758 and rs61886769 of
CYP2C9 as well as microRNA-binding sites and/or RNA binding protein
mediated regulation sites at SNPs rs1934953 of CYP2C8, rs9332242 of
CYP2C9 and rs4244285 of CYP2C19.
4.2. Pathogenetic relationship between SNPs and coronary heart disease
A literature search identified a few studies investigated the role
of the CYP2C gene subfamily in the development of coronary heart
disease (Lee et al., 2007; Ercan et al., 2008; Marciante et al., 2008;
Rothenbacher et al., 2013). Numerous studies considered the studied
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SNP Allele Location
SNP function
prediction
(FuncPred) ⁠a Regulatory annotations on SNPs (rSNPBase) ⁠b Functional in vitro study of SNP [reference]
TFBS miRNA rSNP
LD-proxy
of rSNP
(r⁠2 > 0.8)
Proximal
regulation
Distal
regulation
miRNA
regulation
RNA
binding
protein
mediated
regulation eQTL
CYP2C8
(rs7909236)
G/T Promotor Yes No No Yes No No No No Yes The variant allele T results in the creation
of a CEBPalpha transcription factor
consensus sequence, and is associated with
increased transcription factor binding and
promoter activity (Bahadur et al., 2002;
Kirchheiner et al., 2008)
CYP2C8
(rs1934953)
T/C Intron No No Yes Yes No No No Yes Yes ND
CYP2C9
(rs9332242)
C/G 3′UTR No Yes Yes Yes Yes No No Yes Yes ND
CYP2C9
(rs4918758)
C/T 5′UTR Yes No Yes Yes Yes No No No Yes Allele C is associated with decreased
promoter activity as compared to allele T
(Shintani et al., 2001; Cavallari et al., 2013)
CYP2C9
(rs61886769)
C/T Promotor Yes No No Yes No No No No No ND
CYP2C19
(rs4244285)
A/C/G Exon No No Yes Yes No No No Yes No A synonymous G > A transition in exon 5
that creates an aberrant splice site. This
change alters the mRNA reading frame,
which results in a truncated, non-functional
protein (de Morais et al., 1994)
Data predicted by the SNP Function Prediction tool, National Institute of Environmental Health Sciences (https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.php): TFBS, transcription factor binding site; ND, no data.
Data obtained at rSNPBase, a database of curated regulatory SNPs (http://rsnp.psych.ac.cn): rSNP, rSNPBase identified regulatory SNPs; LD-proxy of rSNP (r⁠2 > 0.8), SNP in strong LD with rSNPs; proximal regulation, SNP involved in proximal transcriptional
regulation; distal regulation, SNP involved in distal transcriptional regulation; miRNA regulation, SNP within mature miRNA; RNA binding protein mediated regulation, SNP involved in RNA binding protein-mediated post-transcriptional regulation; eQTL,
SNP with experimental eQTL evidence.
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genes as candidates for pharmacogenetic investigations of drugs (Hirota
et al., 2013; Backman et al., 2016). Ercan with co-workers investigated
SNPs rs1799853 (CYP2C9*2), rs1057910 (CYP2C9*3) and rs4986893
(CYP2C19*3) and found that cigarette smokers with heterozygote geno-
type for CYP2C9*2 had 3.7-fold risk of developing coronary heart dis-
ease (Ercan et al., 2008). Additionally, the CYP2C19*3 variant (SNP
rs4986893 or rs57081121) was found to associated with a three-fold
risk of coronary atherosclerosis (Ercan et al., 2008). Excepting partic-
ipation in biosynthesis of EETs, CYP2C19 is also involved in the me-
tabolism of a number of drugs such as platelet aggregation antagonists,
proton pump inhibitors, anti-diabetes and anti-cancer drugs (Wei et al.,
2008). SNP rs4244285 of CYP2C19 (CYP2C19*2 allele) represents a
synonymous 681G > A transition in exon 5 that creates an aberrant
splice site altering the mRNA reading frame and resulting in a trun-
cated non-functional protein (de Morais et al., 1994). An apparent pro-
tective effect of this SNP against CHD risk observed in our study can
be interpreted by that the loss-of-function variant of CYP2C19 is related
with decreased enzyme activity and therefore decreased production of
reactive oxygen species (ROS) by this cytochrome P450. Notably, the
similar protective effect of the CYP2C19*2 variant was noted against
the risk of tuberculosis (Backman et al., 2016). Meantime, our find-
ing is inconsistent with the study results of Rothenbacher et al. (2013)
who revealed that patients with stable CHD and homozygous for the
CYP2C19*2 loss-of-function gene have an increased risk for subsequent
myocardial infarction during 8 year follow-up. This means that func-
tional studies on this SNP are required to clarify this inconsistence.
We found that SNP rs4918758 may possess a protective effect
against the CHD risk. Comparing the SNPs constituting each promoter
variants of CYP2C9 against the variants located within putative TFBS,
only two polymorphisms rs4918758 and rs61886769 were found to be
located within potential recognition sites for numerous transcription
factors. In particular, transcription factors CDPCR3, FAC1, LUN1, OCT1,
PPARA, SOX9 and Tal-1beta:E47 have been identified to co-regulate the
promoter activity of CYP2C9 (see Supplementary Tables 2 and 3). These
TFBSs were highlighted because they reduced or increased significantly
matrix match score by the variant allele, as reported in accordance with
the TRANSFAC database. It is known from the literature that allele C
is associated with decreased promoter activity as compared to allele T
(Shintani et al., 2001; Cavallari et al., 2013). Hence, homozygous geno-
type CC may be related with decreased risk of CHD because a decreased
promoter activity of CYP2C9 in such individuals is capable to enhance
ROS production and formation of oxidative stress, an important mecha-
nism of atherosclerosis (Kondo et al., 2009; Li et al., 2014).
4.3. SNP rs9332242-smoking interaction and CHD risk
Lee with co-workers (Lee et al., 2007) observed that cigarette smok-
ing may modify the relationship between common polymorphisms
I264M (rs1058930) and K399R (rs10509681) of CYP2C8 related with
decreased enzyme activity (Gao et al., 2010) and the risk of CHD. An in-
teresting finding of our study was a suggestive association between SNP
rs9332242 of CYP2C9 and CHD risk in cigarette smokers. No functional
in vitro studies were undertaken to analyze the relationship between
polymorphism rs9332242 and expression levels of CYP2C9. We cannot
exclude that the functional effect of SNP rs9332242 can be explained
by linkage disequilibrium with other SNPs: at least 58 SNPs are being
in LD with rs9332242 (r⁠2 > 0.8) in accordance with the rSNPBase data-
base (http://rsnp.psych.ac.cn/snp.do?snp=rs9332242). The SNP Func-
tion Prediction tool allowed identifying TFBS and microRNA-binding
sites located at the rs9332242 polymorphism. In particular, we found
that SNP rs9332242 CYP2C9 is located within binding sites for miR-
NAs such as miR-1321, miR-143, miR-216a, miR-299-3p, miR-552 and
miR-595 as well as within recognition sequences for
numerous putative TFBSs (see Supplementary Table 5). miRNAs are
short non-coding RNAs involved in post-transcriptional regulation of
gene expression most commonly resulting in translational inhibition or
destabilization of the target mRNA. In the light of interpretation of
the SNP-smoking interaction, miR-143 and miR-299-3p attract signifi-
cant attention with respect to a potential dependence of their expres-
sion on smoking exposure. SNP rs9332242 is located at 3′ untrans-
lated region (UTR) of the CYP2C9 gene within miRNA binding site for
miR-143 which was known to be strongly up-regulated in tobacco smok-
ers (Wang et al., 2015). It is also known that smoking may cause sig-
nificant changes in the expression of miR-299-3p whose binding site
comprises SNP rs9332242 (Guled et al., 2009). In addition, the study
of Ercan with co-workers observed a synergic effect of tobacco smok-
ing and SNP rs1799853 on the risk of coronary atherosclerosis (Ercan et
al., 2008). Taken together these data point out that SNPs located within
miRNA target sites (e.g. rs9332242 and rs1799853) may play a pivotal
role in the pathogenesis of smoking-related diseases as miRNAs bind to
3′ UTR regions of genes, thereby regulating their expression (Momi et
al., 2014). It is important to note that miR-552, another miRNA binding
site located at rs9332242, possesses a dual inhibitory ability on the tar-
get genes at transcriptional and post-transcriptional levels. This feature
was demonstrated by the study with effective inhibition of the CYP2E1
gene (Miao et al., 2016) which, like CYP2C9, is also involved in the
formation of EETs from arachidonic acid (Rifkind et al., 1995). Further
studying polymorphism rs9332242 of CYP2C9 and associated miRNAs
in conjunction with the intermodulation between them upon smoking
exposure may help to provide mechanistic insights into the mechanism
by which the locus influences the risk of coronary heart disease in cig-
arette smokers. On the one hand, the synergic effect of smoking expo-
sure and genotype C/G (rs9332242) points out that the G variant in-
creases the activity of CYP2C9 enzyme potentiating a pro-oxidant action
of cigarette smoke through enhanced generation of ROS, oxidative stress
and vascular inflammation. On the other hand, loss-of-function effect of
this SNP may be responsible for a deficiency of EETs which are known
to be involved in endothelium-dependent vasodilation, endothelial sur-
vival via cytoprotective functions, thereby preventing apoptotic and ox-
idative vascular injury (Spiecker and Liao, 2005; Fleming, 2001). In any
case, further studies are required to analyze the functional effects of the
studied SNPs and to confirm our suggestions.
4.4. Study limitations
The results of this study should be interpreted in the context of some
limitations. The associations of the CYP2C9 polymorphisms with CHD
risk were weak, sometimes even suggestive, demonstrating the discov-
ery nature of our study. The study findings do not allow us to draw de-
finitive conclusion on a comprehensive contribution of the studied genes
to the development of coronary heart disease. We investigated a limited
number of SNPs of CYP2C gene subfamily. Because of an insufficient
number of patients in the study groups, we did not perform gene-smok-
ing interaction analysis stratified by gender with an appropriate statisti-
cal power. Hence, the results of our study should be considered as pre-
liminary and further investigation in larger population-based samples is
required to address issues discussed above.
5. Conclusion and perspective
Nevertheless, the present study points out the polymorphisms of
CYP2C9 could be potential genetic markers of susceptibility to coro-
nary heart disease. The relationship between polymorphisms of CYP2C9
gene and CHD risk also demonstrates an importance of epoxygenase
pathway of arachidonic acid metabolism for disease pathogenesis. Bet-
ter understanding the relationships between altered CYP2C9 gene ex-
pression and function in patients with coronary heart disease
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may provide novel insights into disease pathophysiology and suggest
specific targeted interventions that may expand the therapeutic options
for cardiovascular disease in the future.
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